RecruitingPhase 1NCT06014762

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies

Sponsor

Poseida Therapeutics, Inc.

Enrollment

120 participants

Start Date

Apr 16, 2024

Study Type

INTERVENTIONAL

Conditions

High-grade B-cell Lymphoma DLBCL - Diffuse Large B Cell Lymphoma Primary Mediastinal Large B-cell Lymphoma (PMBCL)DLBCL Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Follicular Lymphoma Grade 3B DLBCL NOS Transformed Follicular Lymphoma (tFL)DLBCL Arising From Follicular Lymphoma DLBCL, Diffused Large B Cell Lymphoma

Summary

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing P-CD19CD20-ALLO1, an allogeneic (donor-derived) CAR-T cell therapy that targets two proteins (CD19 and CD20) on B-cell lymphoma cells. It is designed for patients with large B-cell lymphoma or follicular lymphoma grade 3B that has returned or stopped responding to prior treatments. **You may be eligible if...** - You are 18 or older - You have confirmed DLBCL, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, or follicular lymphoma grade 3B - Your cancer has relapsed or is refractory after adequate prior therapy (including an anti-CD20 containing regimen) - You have measurable disease on imaging **You may NOT be eligible if...** - Your disease has never been treated - You have active brain (CNS) lymphoma - Your organ function is significantly impaired - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALP-CD19CD20-ALLO1

Single weight-based IV administration

DRUGRimiducid

Single weight-based IV administration

Locations(17)

University of California San Diego

La Jolla, California, United States

Loma Linda University Cancer Center

Loma Linda, California, United States

Cedars-Sinai Medical Center

Los Angeles, California, United States

Advent Health Orlando

Orlando, Florida, United States

Indiana University

Indianapolis, Indiana, United States

Our Lady of the Lake Hospital

Baton Rouge, Louisiana, United States

Ochsner Clinic Foundation

New Orleans, Louisiana, United States

Wayne State - Karmanos Cancer Institute

Detroit, Michigan, United States

NYU Grossman School of Medicine

New York, New York, United States

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States

University of Cincinnati

Cincinnati, Ohio, United States

University of Oklahoma, Health Sciences Center

Oklahoma City, Oklahoma, United States

Oregon Health & Science University

Portland, Oregon, United States

Pennsylvania State University

Hershey, Pennsylvania, United States

Prisma Health - Upstate Cancer Institute

Greenville, South Carolina, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Baylor Scott & White Research Institute

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06014762

Related Trials

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT060158808 locations

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT0459464227 locations

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017121 locations

A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma

NCT075486971 location

Study of CAR-T Therapy in Older Patients

NCT043009981 location